188 related articles for article (PubMed ID: 35964686)
1. Removal of proteinase K resistant αSyn species does not correlate with cell survival in a virus vector-based Parkinson's disease mouse model.
Eteläinen TS; Kilpeläinen TP; Ignatius A; Auno S; De Lorenzo F; Uhari-Väänänen JK; Julku UH; Myöhänen TT
Neuropharmacology; 2022 Nov; 218():109213. PubMed ID: 35964686
[TBL] [Abstract][Full Text] [Related]
2. Prolyl oligopeptidase inhibition by KYP-2407 increases alpha-synuclein fibril degradation in neuron-like cells.
Rostami J; Jäntti M; Cui H; Rinne MK; Kukkonen JP; Falk A; Erlandsson A; Myöhänen T
Biomed Pharmacother; 2020 Nov; 131():110788. PubMed ID: 33152946
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Prolyl Oligopeptidase Restores Spontaneous Motor Behavior in the α-Synuclein Virus Vector-Based Parkinson's Disease Mouse Model by Decreasing α-Synuclein Oligomeric Species in Mouse Brain.
Svarcbahs R; Julku UH; Myöhänen TT
J Neurosci; 2016 Dec; 36(49):12485-12497. PubMed ID: 27927963
[TBL] [Abstract][Full Text] [Related]
4. A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease.
Myöhänen TT; Hannula MJ; Van Elzen R; Gerard M; Van Der Veken P; García-Horsman JA; Baekelandt V; Männistö PT; Lambeir AM
Br J Pharmacol; 2012 Jun; 166(3):1097-113. PubMed ID: 22233220
[TBL] [Abstract][Full Text] [Related]
5. Human myeloperoxidase (hMPO) is expressed in neurons in the substantia nigra in Parkinson's disease and in the hMPO-α-synuclein-A53T mouse model, correlating with increased nitration and aggregation of α-synuclein and exacerbation of motor impairment.
Maki RA; Holzer M; Motamedchaboki K; Malle E; Masliah E; Marsche G; Reynolds WF
Free Radic Biol Med; 2019 Sep; 141():115-140. PubMed ID: 31175983
[TBL] [Abstract][Full Text] [Related]
6. Prolyl oligopeptidase inhibition attenuates the toxicity of a proteasomal inhibitor, lactacystin, in the alpha-synuclein overexpressing cell culture.
Myöhänen TT; Norrbacka S; Savolainen MH
Neurosci Lett; 2017 Jan; 636():83-89. PubMed ID: 27818354
[TBL] [Abstract][Full Text] [Related]
7. The beneficial effect of a prolyl oligopeptidase inhibitor, KYP-2047, on alpha-synuclein clearance and autophagy in A30P transgenic mouse.
Savolainen MH; Richie CT; Harvey BK; Männistö PT; Maguire-Zeiss KA; Myöhänen TT
Neurobiol Dis; 2014 Aug; 68():1-15. PubMed ID: 24746855
[TBL] [Abstract][Full Text] [Related]
8. The effect of prolyl oligopeptidase inhibitors on alpha-synuclein aggregation and autophagy cannot be predicted by their inhibitory efficacy.
Kilpeläinen TP; Hellinen L; Vrijdag J; Yan X; Svarcbahs R; Vellonen KS; Lambeir AM; Huttunen H; Urtti A; Wallen EAA; Myöhänen TT
Biomed Pharmacother; 2020 Aug; 128():110253. PubMed ID: 32447211
[TBL] [Abstract][Full Text] [Related]
9. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of prolyl oligopeptidase increases the survival of alpha-synuclein overexpressing cells after rotenone exposure by reducing alpha-synuclein oligomers.
Dokleja L; Hannula MJ; Myöhänen TT
Neurosci Lett; 2014 Nov; 583():37-42. PubMed ID: 25240592
[TBL] [Abstract][Full Text] [Related]
11. Alpha-synuclein suppresses mitochondrial protease ClpP to trigger mitochondrial oxidative damage and neurotoxicity.
Hu D; Sun X; Liao X; Zhang X; Zarabi S; Schimmer A; Hong Y; Ford C; Luo Y; Qi X
Acta Neuropathol; 2019 Jun; 137(6):939-960. PubMed ID: 30877431
[TBL] [Abstract][Full Text] [Related]
12. Prolyl oligopeptidase acts as a link between chaperone-mediated autophagy and macroautophagy.
Cui H; Norrbacka S; Myöhänen TT
Biochem Pharmacol; 2022 Mar; 197():114899. PubMed ID: 34968496
[TBL] [Abstract][Full Text] [Related]
13. Removal of prolyl oligopeptidase reduces alpha-synuclein toxicity in cells and in vivo.
Svarcbahs R; Julku UH; Norrbacka S; Myöhänen TT
Sci Rep; 2018 Jan; 8(1):1552. PubMed ID: 29367610
[TBL] [Abstract][Full Text] [Related]
14. Nonpeptidic Oxazole-Based Prolyl Oligopeptidase Ligands with Disease-Modifying Effects on α-Synuclein Mouse Models of Parkinson's Disease.
Kilpeläinen TP; Pätsi HT; Svarcbahs R; Julku UH; Eteläinen TS; Cui H; Auno S; Sipari N; Norrbacka S; Leino TO; Jäntti M; Myöhänen TT; Wallén EAA
J Med Chem; 2023 Jun; 66(11):7475-7496. PubMed ID: 37248563
[TBL] [Abstract][Full Text] [Related]
15. The MHC class II transactivator modulates seeded alpha-synuclein pathology and dopaminergic neurodegeneration in an in vivo rat model of Parkinson's disease.
Jimenez-Ferrer I; Bäckström F; Dueñas-Rey A; Jewett M; Boza-Serrano A; Luk KC; Deierborg T; Swanberg M
Brain Behav Immun; 2021 Jan; 91():369-382. PubMed ID: 33223048
[TBL] [Abstract][Full Text] [Related]
16. Aggregation-Inhibiting scFv-Based Therapies Protect Mice against AAV1/2-Induced A53T-α-Synuclein Overexpression.
Schlichtmann BW; Palanisamy BN; Malovic E; Nethi SK; Padhi P; Hepker M; Wurtz J; John M; Ban B; Anantharam V; Kanthasamy AG; Narasimhan B; Mallapragada SK
Biomolecules; 2023 Jul; 13(8):. PubMed ID: 37627268
[TBL] [Abstract][Full Text] [Related]
17. Glucocerebrosidase deficiency accelerates the accumulation of proteinase K-resistant α-synuclein and aggravates neurodegeneration in a Drosophila model of Parkinson's disease.
Suzuki M; Fujikake N; Takeuchi T; Kohyama-Koganeya A; Nakajima K; Hirabayashi Y; Wada K; Nagai Y
Hum Mol Genet; 2015 Dec; 24(23):6675-86. PubMed ID: 26362253
[TBL] [Abstract][Full Text] [Related]
18. 14-3-3 Proteins Reduce Cell-to-Cell Transfer and Propagation of Pathogenic α-Synuclein.
Wang B; Underwood R; Kamath A; Britain C; McFerrin MB; McLean PJ; Volpicelli-Daley LA; Whitaker RH; Placzek WJ; Becker K; Ma J; Yacoubian TA
J Neurosci; 2018 Sep; 38(38):8211-8232. PubMed ID: 30093536
[TBL] [Abstract][Full Text] [Related]
19. Transmissible α-synuclein seeding activity in brain and stomach of patients with Parkinson's disease.
Thomzig A; Wagenführ K; Pinder P; Joncic M; Schulz-Schaeffer WJ; Beekes M
Acta Neuropathol; 2021 Jun; 141(6):861-879. PubMed ID: 33895878
[TBL] [Abstract][Full Text] [Related]
20. Galectin-3 shapes toxic alpha-synuclein strains in Parkinson's disease.
García-Revilla J; Boza-Serrano A; Jin Y; Vadukul DM; Soldán-Hidalgo J; Camprubí-Ferrer L; García-Cruzado M; Martinsson I; Klementieva O; Ruiz R; Aprile FA; Deierborg T; Venero JL
Acta Neuropathol; 2023 Jul; 146(1):51-75. PubMed ID: 37202527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
